For years, researchers have been moving towards decentralized clinical trials (DCTs), and in a matter of months, COVID-19 changed the trajectory. Clinical operations teams and investigator sites around the world rose to the challenge and worked quickly to deploy new tactics to serve their study participants. The resulting reward is that DCTs, which can be leveraged smartly to reduce participant burden and improve recruitment and retention, are now becoming more widely adopted in design considerations. But rewards bring about new risks and challenges, and DCTs create new concerns for monitoring participant safety. Dario Lirio – Senior Director, LifeSphere Clinical at ArisGlobal – analyzes the risks and rewards of DCTs.
If you are not happy with the results below please do another search
50 search results for:
Half of the COVID-19 patients discharged from a Chinese hospital in early 2020 still have at least one symptom two years later, a new study shows. Additionally, new findings suggest patterns of inflammatory proteins in the blood of people with long COVID may someday help guide individualized treatment.
If you flip through history, you’ll realize that our fundamental healthcare needs haven’t changed since the year 1885. We still seek rest when we’re ill, feel pain when we overexert ourselves, and need guidance from experts on our health and wellness. But the tools we have to meet these perennial needs have shifted dramatically since the 19th century, and especially over the past decade, wherein technology has advanced faster than even the greatest Sci-Fi film producers imagined, according to Greater Than One Chief Technology Officer Ken Winell.
Klick Health hired 37-time Cannes Lions and 80-time Clio awards recipient Bernardo Romero to become the agency’s ‘Maker’ – a role that was specially created around his desire to return to creating campaigns and products that positively impact people’s health. Romero, who was Chief Creative Officer at The Bloc, wants to bring his patient experience as someone who has diabetes into his work. Romero and Klick Health Chief Creative Officer Rich Levy talked to Med Ad News about what brought Romero to Klick and the launch of The Workshop, a Klick team of “Makers, Concepters, Noodlers and Doodlers” that will be experimenting with new ideas for creative healthcare advertising.
Cullinan Oncology and Taiho Pharmaceutical announced that Taiho was acquiring Cullinan Pearl and will co-develop and co-commercialize a non-small cell lung cancer (NSCLC) drug.
BridgeBio announced that the Palo Alto, Calif.-based biopharmaceutical company signed an exclusive deal with Bristol Myers Squibb to develop and commercialize a potential treatment for cancer.
The United States will share technologies used to make COVID-19 vaccines through the World Health Organization and is working to expand rapid testing and antiviral treatments for hard-to-reach populations, President Joe Biden said on May 12.
Several generic drugmakers that will produce versions of Pfizer’s COVID-19 antiviral treatment Paxlovid agreed to sell the medicine in low-income and middle-income countries for $25 a course or less, the Clinton Health Access Initiative (CHAI) said on May 12.
The World Health Organization on May 12 said COVID-19 deaths have exceeded the 2 million mark for countries in the WHO European Region.
President Joe Biden on May 12 commemorated the death of 1 million people in the United States from COVID-19, marking what he called “a tragic milestone” and urging Americans to “remain vigilant” amid the ongoing pandemic.